Browsing by Author "Zanin, Mark"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Cell-based neurotrophin treatment for auditory neuron survival in deafness
    (2012) Gillespie, Lisa; Zanin, Mark; Shepherd, Robert
    The cochlear implant provides auditory cues to patients with profound hearing loss by electrically stimulating the auditory neurons within the cochlea, but the ongoing regeneration of auditory neurons that occurs in sensorineural hearing loss may be a limiting factor in cochlear implant efficacy. The exogenous application of neurotrophins such as BDNF can rescue auditory neurons from this deafness induced degeneration; however, these survival effects are not maintained. A safe and efficient means of delivering neurotrophins to the cochlea, which can be used in conjunction with a cochlear implant for long-term survival of auditory neurons, is required for this therapy to be clinically transferable. We investigated the survival-promoting effects of cell-based neurotrophin treatment and electrical stimulation, using fibroblasts genetically modified to express BDNF and encapsulated in a biocompatible matrix, on auditory neurons in the deaf guinea pig.
  • Thumbnail Image
    Item
    Cell-based neurotrophin treatment supports long-term auditory neuron survival in the deaf guinea pig
    (Elsevier B.V, 2015-01-28) Gillespie, Lisa; Zanin, Mark; Shepherd, Robert
    The cochlear implant provides auditory cues to profoundly deaf patients by electrically stimulating the primary auditory neurons (ANs) of the cochlea. However, ANs degenerate in deafness; the preservation of a robust AN target population, in combination with advances in cochlear implant technology, may provide improved hearing outcomes for cochlear implant patients. The exogenous delivery of neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3 is well known to support AN survival in deafness, and cell-based therapies provide a potential clinically viable option for delivering neurotrophins into the deaf cochlea. This study utilised cells that were genetically modified to express BDNF and encapsulated in alginate microspheres, and investigated AN survival in the deaf guinea pig following (a) cell-based neurotrophin treatment in conjunction with chronic electrical stimulation from a cochlear implant, and (b) long-term cell-based neurotrophin delivery. In comparison to deafened controls, there was significantly greater AN survival following the cell-based neurotrophin treatment, and there were ongoing survival effects for at least six months. In addition, functional benefits were observed following cell-based neurotrophin treatment and chronic electrical stimulation, with a statistically significant decrease in electrically evoked auditory brainstem response thresholds observed during the experimental period. This study demonstrates that cell-based therapies, in conjunction with a cochlear implant, shows potential as a clinically transferable means of providing neurotrophin treatment to support AN survival in deafness. This technology also has the potential to deliver other therapeutic agents, and to be used in conjunction with other biomedical devices for the treatment of a variety of neurodegenerative conditions.
  • Thumbnail Image
    Item
    Cell-based neurotrophin treatment supports long-term auditory neuron survival in the deaf guinea pig.
    (Elsevier B.V., 2015-01) Gillespie, Lisa; Zanin, Mark; Shepherd, Robert
    The cochlear implant provides auditory cues to profoundly deaf patients by electrically stimulating the primary auditory neurons (ANs) of the cochlea. However, ANs degenerate in deafness; the preservation of a robust AN target population, in combination with advances in cochlear implant technology, may provide improved hearing outcomes for cochlear implant patients. The exogenous delivery of neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3 iswell known to support AN survival in deafness, and cell-based therapies provide a potential clinically viable option for delivering neurotrophins into the deaf cochlea. This study utilized cells that were genetically modified to express BDNF and encapsulated in alginate microspheres, and investigated AN survival in the deaf guinea pig following (a) cell-based neurotrophin treatment in conjunction with chronic electrical stimulation from a cochlear implant, and (b) long-term cell-based neurotrophin delivery. In comparison to deafened controls, there was significantly greater AN survival following the cell-based neurotrophin treatment, and there were ongoing survival effects for at least six months. In addition, functional benefits were observed following cell-based neurotrophin treatment and chronic electrical stimulation, with a statistically significant decrease in electrically evoked auditory brainstem response thresholds observed during the experimental period. This study demonstrates that cell-based therapies, in conjunction with a cochlear implant, shows potential as a clinically transferable means of providing neurotrophin treatment to support AN survival in deafness. This technology also has the potential to deliver other therapeutic agents, and to be used in conjunction with other biomedical devices for the treatment of a variety of neurodegenerative conditions.
  • Thumbnail Image
    Item
    Development of a cell-based treatment for long-term neurotrophin expression and spiral ganglion neuron survival.
    (Elsevier, 2014-09) Zanin, Mark; Hellstrom, Mats; Shepherd, Robert; Harvey, Allan; Gillespie, Lisa
    Spiral ganglion neurons (SGNs), the target cells of the cochlear implant, undergo gradual degeneration following loss of the sensory epithelium in deafness. The preservation of a viable population of SGNs in deafness can be achieved in animal models with exogenous application of neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3. For translation into clinical application, a suitable delivery strategy that provides ongoing neurotrophic support and promotes long-term SGN survival is required. Cell-based neurotrophin treatment has the potential to meet the specific requirements for clinical application, and we have previously reported that Schwann cells genetically modified to express BDNF can support SGN survival in deafness for 4 weeks. This study aimed to investigate various parameters important for the development of a long-term cell-based neurotrophin treatment to support SGN survival. Specifically, we investigated different (i) cell types, (ii) gene transfer methods and (iii) neurotrophins, in order to determine which variables may provide long-term neurotrophin expression and which, therefore, may be the most effective for supporting long-term SGN survival in vivo. We found that fibroblasts that were nucleofected to express BDNF provided the most sustained neurotrophin expression, with ongoing BDNF expression for at least 30 weeks. In addition, the secreted neurotrophin was biologically active and elicited survival effects on SGNs in vitro. Nucleofected fibroblasts may therefore represent a method for safe, long-term delivery of neurotrophins to the deafened cochlea to support SGN survival in deafness.
  • Thumbnail Image
    Item
    The development of encapsulated cell technologies as therapies for neurological and sensory diseases
    (Elsevier, 2012-02) Zanin, Mark; Pettingill, Lisa; Harvey, Alan; Emerich, Dwaine; Thanos, Christopher; Shepherd, Robert
    Cell encapsulation therapies involve the implantation of cells that secrete a therapeutic factor to provide clin- ical benefits. The transplanted cells are protected from immunorejection via encapsulation in a semiperme- able membrane. This treatment strategy was originally investigated as a method for protecting pancreatic islets from immunorejection, thus allowing them to secrete insulin as a chronic treatment for diabetes. Since then a significant body of work has been conducted in developing cell encapsulation therapies to treat a variety of different diseases. Many of these conditions involve neurodegeneration, such as Alzheimer's and Parkinson's disease, as cell encapsulation therapies have proven to be particularly suitable for delivering thera- peutics to the central nervous system. This is mainly because they offer chronic delivery of a therapeutic and can be implanted proximal to the affected tissue, bypassing the blood brain barrier, which is impermeable to many agents. Whilst these therapies are not yet widely available in the clinic, promising results have been obtained in several advanced clinical trials and further developmental work is currently underway. This review specifically examines the development of encapsulated cell therapies as treatments for neurological and sensory diseases and evaluates the challenges that are yet to be overcome before they can be made available for clinical use.